Core Viewpoint - The company has announced an investment in BoRuiKang Technology (Shanghai) Co., Ltd., focusing on brain-machine interface technology, which is expected to enhance its medical-related project portfolio [1] Group 1: Investment Details - China Merchants China Fund's wholly-owned subsidiary, Shenzhen Tianzheng Investment Co., Ltd., signed a share purchase agreement with BoRuiKang Technology, agreeing to invest 15 million RMB in its E-round financing [1] - The investment was completed on November 7, 2025 [1] Group 2: Company Overview - BoRuiKang Technology, established in November 2011, specializes in the research, development, production, and sales of brain-machine interface systems and related equipment [1] - The company aims to provide comprehensive solutions for innovative research in neuroscience and clinical diagnosis, treatment, and rehabilitation of neurological diseases [1] Group 3: Market Position and Recognition - BoRuiKang Technology has accumulated significant technical reserves and development experience in the brain-machine interface field over the years [1] - Its products are applicable in various research fields, including neuroscience, psychology, human factors engineering, kinesiology, and management, as well as in clinical medicine for diagnosing and treating neurological diseases [1] - The company's research achievements and technical capabilities have been widely recognized by experts in the fields of neural engineering and clinical medicine both domestically and internationally [1] Group 4: Strategic Implications - The investment in BoRuiKang Technology is expected to increase the proportion of medical-related projects within the company's investment portfolio, optimizing its overall investment strategy [1]